Clinically relevant resistance in cancer chemotherapy
Read Online
Share

Clinically relevant resistance in cancer chemotherapy

  • 178 Want to read
  • ·
  • 24 Currently reading

Published by Kluwer Academic in Boston .
Written in English

Subjects:

  • Drug resistance in cancer cells.,
  • Drug Resistance, Neoplasm -- physiology.,
  • Neoplasms -- drug therapy.

Book details:

Edition Notes

Includes bibliographical references and index.

Statementedited by Borje Andersson and David Murray.
SeriesCancer treatment and research
ContributionsAndersson, Börje., Murray, David, Ph.D.
Classifications
LC ClassificationsRC271.C5 C5525 2002
The Physical Object
Paginationxx, 380 p. :
Number of Pages380
ID Numbers
Open LibraryOL19288403M
ISBN 101402072007
LC Control Number2002030025

Download Clinically relevant resistance in cancer chemotherapy

PDF EPUB FB2 MOBI RTF

The failure of chemotherapy to cure metastatic cancer is commonly referred to among clinicians as "drug resistance". This phenomenon can, however, often be viewed as the survival of malignant cells that resulted from a failure to deliver an effective drug dose to the (cellular) target because of anyone of or combination of a multitude of. Clinically Relevant Resistance in Cancer Chemotherapy. por. Cancer Treatment and Research (Book ) ¡Gracias por compartir! Has enviado la siguiente calificación y reseña. Lo publicaremos en nuestro sitio después de haberla : Springer US. Download Provides a clear and accessible summary of all stages and aspects of the discovery, design, development, validation and clinical use of anticancer drugs This new edition provides an update on the current state of the art of cancer chemotherapy and clinical practice and presents new pipeline anticancer agents and promising therapeutic strategies that are emerging alongside new. Clinical trials have been initiated with agents that may inhibit the biochemical mechanisms of acquired drug resistance. Clinical trials are already in progress with alkylating agents combined with inhibition of GSH biosynthesis (i.e., buthionine sulfoximine) or enzymatic inhibitors of glutathione S‐transferase activity (i.e., ethacrynic acid).Cited by:

In general, resistance to traditional cytotoxic therapy is accomplished by decreasing the delivery of drug to the cancer cell, either by increased efflux out of the cell mediated by ATP-dependent transporters, by decreased uptake into the cell, or by a change in enzymes involved in by:   However, resistance to platinum-based drugs often arises due to nucleotide excision repair and homologous recombination, the primary DNA repair mechanisms involved in reversing platinum damage [ 51, 52, 53 ]. Thus, the efficacy of DNA-damaging cytotoxic drugs depends on the failure of the cancer cell’s DDR by: 2 hours ago  MCL-1 overexpression is implicated as a resistance factor for multiple therapies including widely prescribed microtubule-targeted agents for breast cancers. which displays clinically relevant. COVID Resources. Reliable information about the coronavirus (COVID) is available from the World Health Organization (current situation, international travel).Numerous and frequently-updated resource results are available from this ’s WebJunction has pulled together information and resources to assist library staff as they consider how to handle coronavirus.

Clinically Relevant Resistance in Cancer Chemotherapy. [Borje Andersson; David Murray] -- The present volume reviews clinically relevant aspects of the pharmacokinetics of commonly used anticancer agents as well as mechanisms of cellular/experimental resistance to such agents. Clinically Relevant Resistance in Cancer Chemotherapy | Over the last several decades, the introduction of new chemotherapeutic drugs and drug combinations has resulted in increased long- term remission rates in several important tumor types. Abstract. ▪ Abstract The design of cancer chemotherapy has become increasingly sophisticated, yet there is no cancer treatment that is % effective against disseminated cancer. Resistance to treatment with anticancer drugs results from a variety of factors including individual variations in patients and somatic cell genetic differences in tumors, Cited by:   Dahlgren and colleagues aimed to characterize ESR1 resistance mutations in primary breast cancer, chemotherapy. Mutant allele frequencies ranged from 2% to %. clinically relevant .